Efficacy News and Research

RSS
Study explores omicron-reactive T- and B- cell responses in COVID-19 vaccine recipients

Study explores omicron-reactive T- and B- cell responses in COVID-19 vaccine recipients

Evaluating delayed vaccination schedules for protection against SARS-CoV-2

Evaluating delayed vaccination schedules for protection against SARS-CoV-2

Northwestern researchers study COVID-19 mechanisms, infection patterns and impact on gender minorities

Northwestern researchers study COVID-19 mechanisms, infection patterns and impact on gender minorities

Researchers discover a new function of anti-HIV-1 antibodies

Researchers discover a new function of anti-HIV-1 antibodies

A novel approach to predict mutations within the SARS-CoV-2 spike

A novel approach to predict mutations within the SARS-CoV-2 spike

AI systems may one day assist anesthesiologists in the operating room, study suggests

AI systems may one day assist anesthesiologists in the operating room, study suggests

Greater neutralizing titers observed in vaccinated individuals with breakthrough Omicron infection

Greater neutralizing titers observed in vaccinated individuals with breakthrough Omicron infection

mRNA booster vaccination shown to induce robust neutralizing antibodies against SARS-CoV-2 omicron variant

mRNA booster vaccination shown to induce robust neutralizing antibodies against SARS-CoV-2 omicron variant

Study finds the vaccine effectiveness of 3 COVID-19 vaccines to be lower than earlier estimates

Study finds the vaccine effectiveness of 3 COVID-19 vaccines to be lower than earlier estimates

Exploring the comparative efficacy of booster vaccines against SARS-CoV-2 Omicron and Delta variants

Exploring the comparative efficacy of booster vaccines against SARS-CoV-2 Omicron and Delta variants

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

Researchers develop influenza virus-like particle-based hybrid vaccine for both influenza and SARS-CoV-2 viruses

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Evaluating effects of D614G and P681R/H mutations on SARS-CoV-2 VOCs

Evaluating effects of D614G and P681R/H mutations on SARS-CoV-2 VOCs

SARS-CoV-2 human challenge study offers novel insights into viral kinetics

SARS-CoV-2 human challenge study offers novel insights into viral kinetics

Better diagnostic tests needed to guide HER2 breast cancer treatment, study suggests

Better diagnostic tests needed to guide HER2 breast cancer treatment, study suggests

Nuvaxovid COVID-19 vaccine given regulatory approval By MHRA

Nuvaxovid COVID-19 vaccine given regulatory approval By MHRA

Studying the efficacy of a SARS-CoV-2 vaccine booster dose

Studying the efficacy of a SARS-CoV-2 vaccine booster dose

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

Booster dose of Covaxin vaccine candidate neutralizes Omicron and Delta variants

Booster dose of Covaxin vaccine candidate neutralizes Omicron and Delta variants

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.